Q1 2017 Earnings Forecast for CVS Health Corporation (CVS) Issued By Leerink Swann

CVS Health Corporation (NYSE:CVS) – Investment analysts at Leerink Swann reduced their Q1 2017 EPS estimates for shares of CVS Health Corporation in a research report issued to clients and investors on Thursday. Leerink Swann analyst D. Larsen now anticipates that the firm will post earnings per share of $1.09 for the quarter, down from their previous estimate of $1.10. Leerink Swann currently has a “Buy” rating and a $90.00 price target on the stock. Leerink Swann also issued estimates for CVS Health Corporation’s Q3 2017 earnings at $1.65 EPS and FY2018 earnings at $6.40 EPS.

CVS Health Corporation (NYSE:CVS) last posted its earnings results on Thursday, February 9th. The pharmacy operator reported $1.71 EPS for the quarter, beating the consensus estimate of $1.67 by $0.04. CVS Health Corporation had a return on equity of 17.55% and a net margin of 3.00%. The firm had revenue of $46 billion for the quarter, compared to analysts’ expectations of $46.56 billion. During the same period last year, the firm earned $1.53 EPS. The firm’s revenue was up 11.7% compared to the same quarter last year.

This piece was reported by sleekmoney and is the sole property of of sleekmoney. If you are viewing this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be viewed at http://sleekmoney.com/q1-2017-earnings-forecast-for-cvs-health-corporation-cvs-issued-by-leerink-swann/1659575.html.

Earnings History and Estimates for CVS Health Corporation (NYSE:CVS)

CVS has been the topic of several other reports. Atlantic Securities cut shares of CVS Health Corporation from an “overweight” rating to a “neutral” rating and set a $84.00 target price on the stock. in a report on Monday, February 6th. Robert W. Baird cut shares of CVS Health Corporation from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $86.00 to $77.00 in a research note on Thursday, February 2nd. Vetr raised shares of CVS Health Corporation from a “buy” rating to a “strong-buy” rating and set a $98.36 price objective on the stock in a research note on Monday, October 24th. Deutsche Bank AG reissued a “hold” rating and issued a $99.00 price objective (down from $108.00) on shares of CVS Health Corporation in a research note on Tuesday, October 18th. Finally, Mizuho lifted their price objective on shares of CVS Health Corporation from $90.00 to $111.00 and gave the company a “buy” rating in a research note on Wednesday, November 9th. Seven equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $95.72.

Shares of CVS Health Corporation (NYSE:CVS) opened at 78.70 on Monday. CVS Health Corporation has a 52-week low of $69.30 and a 52-week high of $106.67. The company has a 50-day moving average price of $79.79 and a 200 day moving average price of $84.92. The firm has a market capitalization of $83.50 billion, a PE ratio of 16.03 and a beta of 0.85.

Large investors have recently bought and sold shares of the stock. Compass Capital Management Inc. increased its stake in CVS Health Corporation by 5.1% in the second quarter. Compass Capital Management Inc. now owns 208,052 shares of the pharmacy operator’s stock valued at $19,919,000 after buying an additional 10,077 shares during the period. Savant Capital LLC increased its stake in CVS Health Corporation by 13.3% in the second quarter. Savant Capital LLC now owns 9,767 shares of the pharmacy operator’s stock valued at $935,000 after buying an additional 1,148 shares during the period. Trillium Asset Management LLC increased its stake in CVS Health Corporation by 4.9% in the second quarter. Trillium Asset Management LLC now owns 183,362 shares of the pharmacy operator’s stock valued at $17,555,000 after buying an additional 8,555 shares during the period. Premier Fund Managers Ltd increased its stake in CVS Health Corporation by 30.8% in the second quarter. Premier Fund Managers Ltd now owns 34,000 shares of the pharmacy operator’s stock valued at $3,209,000 after buying an additional 8,000 shares during the period. Finally, Whittier Trust Co. increased its stake in CVS Health Corporation by 1.9% in the second quarter. Whittier Trust Co. now owns 155,102 shares of the pharmacy operator’s stock valued at $14,849,000 after buying an additional 2,893 shares during the period. 81.29% of the stock is owned by hedge funds and other institutional investors.

This piece was reported by sleekmoney and is the sole property of of sleekmoney. If you are viewing this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be viewed at http://sleekmoney.com/q1-2017-earnings-forecast-for-cvs-health-corporation-cvs-issued-by-leerink-swann/1659575.html.

The business also recently declared a quarterly dividend, which was paid on Thursday, February 2nd. Shareholders of record on Tuesday, January 24th were paid a $0.50 dividend. This is an increase from CVS Health Corporation’s previous quarterly dividend of $0.43. This represents a $2.00 annualized dividend and a yield of 2.54%. The ex-dividend date was Friday, January 20th. CVS Health Corporation’s payout ratio is 40.65%.

About CVS Health Corporation

CVS Health Corporation, together with its subsidiaries (CVS Health), is a pharmacy company. The Company operates through three business segments: Pharmacy Services, Retail/LTC and Corporate. The Company offers a range of products and services, such as advising patients on their medications at its CVS Pharmacy locations, introducing programs to help control costs for its clients at CVS Caremark, how care is delivered to its patients with conditions through CVS Specialty, pharmacy care for the senior community through Omnicare.

5 Day Chart for NYSE:CVS

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/q1-2017-earnings-forecast-for-cvs-health-corporation-cvs-issued-by-leerink-swann/1659575.html

Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *